Italia markets closed

GLTO May 2024 2.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,01000,0000 (0,00%)
In data: 11:34AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,0100
Aperto0,0100
Denaro0,0000
Lettera0,0500
Prezzo d'esercizio2,50
Scadenza2024-05-17
Min-Max giorno0,0100 - 0,0100
Contratto - Min-MaxN/D
Volume4
Open Interest261
  • GlobeNewswire

    Galecto Announces Plans to Explore Strategic Alternatives

    BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, Galecto

  • GlobeNewswire

    Galecto to Present at Investor Conferences in September

    BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings. H.C. Wainwright 25th Annual Global Investment ConferenceDate

  • GlobeNewswire

    Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

    Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis (IPF). The GALACTIC-1 trial did n